Clarity develops a non-invasive neuromodulation platform designed to influence brain rhythms associated with neurodegenerative disease. The company’s approach uses synchronized light and sound stimulation delivered through a wearable system, including virtual reality–based environments, to engage neural circuits implicated in cognitive decline without surgical intervention. Clarity positions its technology within regulated clinical research and therapeutic development contexts.

The technology delivers rhythmic audiovisual stimulation at 40 Hz, a frequency associated with gamma-band neural activity. By entraining brain rhythms through sensory pathways, the system aims to modulate neural network function linked to cognition and memory. Stimulation is delivered via immersive, software-controlled protocols rather than direct electrical stimulation or invasive recording, leveraging patterned sensory input to influence neural dynamics.

Clarity targets neurological conditions such as Alzheimer’s disease and related disorders where disruptions in brain rhythms are implicated. The platform is intended for use within clinical trials and therapeutic evaluation rather than consumer wellness, reflecting broader interest in non-invasive neuromodulation approaches that aim to restore network-level brain function through rhythmic stimulation.